Phreesia, Inc. ($PHR) has become a household name in the medical industry due to its innovative patient check-in solutions that are transforming the way healthcare clinics and medical practitioners deliver their services. The company offers a range of products designed to streamline and digitize the patient check-in process, resulting in improved efficiency and outstanding patient experiences.
The firm’s products suite consists of registration, appointment scheduling, clinical support, revenue cycle management, privacy and security, integration, analytics and reports as well as patient surveys. They offer these solutions across health systems as well as privately-owned multi-specialty clinics.
Financially speaking, Phreesia did not disappoint when it released its earnings for Q1 2021 on March 22nd. Despite generating $76.59 million in revenue during the quarter (a significant increase compared to estimates there was still an operating loss of ($0.72) EPS; notwithstanding this less-than-favorable bottom line figure the firm still topped consensus estimates with actual earning per share ($0.06) higher than predicted. Financial experts have predicted a further decline throughout the fiscal year 2021 with expectations that Phreesia will ultimately end up posting earnings per share in the red denoting not only financial loss but undoubtedly a disappointment to investors.
However hedge funds seem unperturbed by eroding coffers; Barclays PLC raised its holdings in shares of Phreesia by 11% during Q3 while both FourThought Financial LLC saw 16% growth during this same period , Captrust “relatively speaking”, outperformed them all with their stocks outclassing other fund managers via a staggering shrewd investment decision displaying impressive foresight seeing their investments grow nearly $30k before those companies noted above could amass even half so much.
Accordingly, numbers (indicative of headcount) don’t lie – over ninety percent of Phreesia’s stockholders are institutional investors and hedge funds. This means that the company retains a very large degree of interest in the financial sector, whose stakeholders are drawn by its predominantly untapped opportunities.
The market sees Phreesia as a Moderate Buy opportunity with an average target price of $38.07; its share price has fluctuated between $13.19-40 over the last year, closing at $33.80 on Friday the 22nd January while its fifty-day moving average is placed at $33.95, having come off its two hundred-day moving average of $31.25 after strong revenue-generating quarters ended March 2021.
In summation, Phreesia seems poised to continue disrupting the medical industry; its proprietary technology has already improved efficiencies and patient experiences across various health institutions, indicating why it is such a go-to for large-scale investment firms whose buy-ins have bolstered what could have been construed as weak earnings numbers reported over Q1 of fiscal year ending 2021.’
Leave a Reply